Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical
cancer (CC) after failure of platinum-based regimen treatment.